Products classification
ABOUT US
Email:
sales@ruixibiotech.com
Tel.:
02988811435
Home > products > apis> gpcr-g-protein
Catalog name Description price
R-R-4217 CCR3 antagonist 1 CAS No.879399-82-3 CCR3 antagonist 1/CAS No.879399-82-3 is a potent antagonist of CCR3, used for the research of immunologic and inflammatory diseases. price>
R-R-4218 Maraviroc-d6 CAS No.1033699-22-7 Maraviroc-d6 (UK-427857-d6)/CAS No.1033699-22-7 is the deuterium labeled Maraviroc. Maraviroc (UK-427857) is a selective CCR5 antagonist with activity against human HIV. price>
R-R-4219 CKLF1-C27 CAS No.891861-48-6 CKLF1-C27/CAS No.891861-48-6, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway. CKLF1-C27 can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 shows great effect on promoting proliferation on HUVECs. CKLF1-C27 has the potential for psoriasis research. price>
R-R-4220 α-NETA CAS No.115066-04-1 α-NETA/CAS No.115066-04-1 is a potent and noncompetitive choline acetyltransferase (ChA) inhibitor with an IC50 of 9 μM. α-NETA is a potent ALDH1A1 (IC50=0.04 µM) and chemokine-like receptor-1 (CMKLR1) antagonist. α-NETA weakly inhibits cholinesterase (ChE; IC50=84 µM) and acetylcholinesterase (AChE; IC50=300 µM). α-NETA has anti-cancer activity. price>
R-R-4221 Devazepide CAS No.103420-77-5 Devazepide (L-364,718)/CAS No.103420-77-5 is a potent, competitive, selective and orally active nonpeptide antagonist of cholecystokinin (CCK) receptor, with IC50s of 81 pM, 45 pM and 245 nM for rat pancreatic, bovine gallbladder and guinea pig brain CCK receptors, respectively. Devazepide (L-364,718) is effective for gastrointestinal disorders. price>
R-R-4222 Sograzepide CAS No.155488-25-8 Sograzepide (Netazepide; YF 476; YM-220)/CAS No.155488-25-8 is an extremely potent , highly selective and orally active Gastrin/CCK-B antagonist with an IC50 value of 0.1 nM, has inhibitory effect on Gastrin/CCK-A activity with an IC50 of 502 nM. Sograzepide (Netazepide; YF 476; YM-220) replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine and cloned human Gastrin/CCK-B receptors, with Ki values of 0.068, 0.62 and 0.19 nM, respectively. price>
R-R-4223 L-365260 CAS No.118101-09-0 L-365260/CAS No.118101-09-0 is an orally active and selective antagonist of non-peptide gastrin and brain cholecystokinin receptor (CCK-B), with Kis of 1.9 nM and 2.0 nM, respectively. L-365260 interacts in a stereoselective and competitive manner with guinea pig stomach gastrin and brain CCK receptors. L-365260 can enhance Morphine analgesia and prevents Morphine tolerance. price>
R-R-4224 Proglumide sodium CAS No.99247-33-3 Proglumide sodium/CAS No.99247-33-3 is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide sodium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide sodium also has antiepileptic and antioxidant activities. price>
R-R-4225 Proglumide CAS No.6620-60-6 Proglumide/CAS No.6620-60-6 is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide selective blocks CCK’s effects in the central nervous system (CNS). Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide also has antiepileptic and antioxidant activities. price>
R-R-4226 SR 146131 CAS No.221671-61-0 SR 146131/CAS No.221671-61-0 is a potent, orally available, and selective nonpeptide (cholecystokinin 1) receptor agonist. price>